UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against OvaScience, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of August 5, 2014 -- OVAS

NEW YORK, NY--(Marketwired - Jun 30, 2014) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company") (NASDAQ: OVAS) securities between February 25, 2013 and September 10, 2013.

For more information, click here: http://zlk.9nl.com/ovascience.

The complaint alleges that defendants made materially false and misleading statements regarding the Company's business and operations. In particular, OvaScience represented to investors and the Food and Drug Administration that its fertility treatment AUGMENT would likely qualify for designation as a 361 HCT/P, which allows human cellular and tissue based products to be tested and marketed without FDA licensure.

On September 10, 2013, the Company disclosed the receipt of a letter from the FDA in which the status of AUGMENT as a 361 HCT/P was questioned. The FDA also requested that OvaScience file an Investigational New Drug (IND) application, thus ensuring that the drug face mandatory clinical testing.

If you suffered a loss in OvaScience you have until August 5, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ovascience.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.